Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 6.5M | 1.5% |
| Net Income | -6.4M | 1.5% |
| EBITDA | -6.5M | 2.7% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 8.3M | 46.5% |
| Total Liabilities | 9.8M | 9.4% |
| Shares Outstanding | 1.5M | 0% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -6.6M | 14.2% |
EPS
Financial Highlights for Aptevo Therapeutics in Q1 '25
Operating Expenses for this period were 6.5M, showing a 1.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -6.4M, showing a -1.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -6.5M, showing a -2.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Aptevo Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
